C34 is a TLR4 inhibitor, which inhibited TLR4 in enterocytes and macrophages in vitro, and reduced systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.
C34 is a TLR4 inhibitor, which inhibited TLR4 in enterocytes and macrophages in vitro, and reduced systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.
C34 is a TLR4 inhibitor, which inhibited TLR4 in enterocytes and macrophages in vitro, and reduced systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.
C34 is a TLR4 inhibitor, which inhibited TLR4 in enterocytes and macrophages in vitro, and reduced systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.
TLR7-agonist-1 is a potent and selective Toll-like Receptor 7 (TLR7) agonist with a LEC of 0.4 μM.
TLR7-agonist-1 is a potent and selective Toll-like Receptor 7 (TLR7) agonist with a LEC of 0.4 μM.
TLR7/8 agonist 1 dihydrochloride is a dual agonist of toll-like receptor TLR7/TLR8.
TLR7/8 agonist 1 dihydrochloride is a dual agonist of toll-like receptor TLR7/TLR8.
TLR7/8 agonist 1 dihydrochloride is a dual agonist of toll-like receptor TLR7/TLR8.
TM38837 is an orally active, peripherally restricted cannabinoid receptor type 1 (CB1) receptor antagonist.TM38837 has limited penetration into the brain and minimizes or prevents CNS adverse effects.
TM38837 is an orally active, peripherally restricted cannabinoid receptor type 1 (CB1) receptor antagonist.TM38837 has limited penetration into the brain and minimizes or prevents CNS adverse effects.
TM38837 is an orally active, peripherally restricted cannabinoid receptor type 1 (CB1) receptor antagonist.TM38837 has limited penetration into the brain and minimizes or prevents CNS adverse effects.